{"version":"1.0","type":"link","title":"A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.","author_name":"Xue R 외","author_url":"https://prs-insight.online/author/Xue%20R","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/150367","thumbnail_width":1200,"thumbnail_height":630}